{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:21Z","timestamp":1787028561447,"version":"build-2736575974"},"reference-count":86,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Asthma is among the most common chronic respiratory diseases, affecting approximately 3340 individuals per 100,000 worldwide. It is a heterogeneous condition associated with airway hyperresponsiveness and chronic inflammation. Severe asthma (SA) affects 3\u201310% of patients, most of whom exhibit Type 2 (T2) inflammation with elevated eosinophil counts or increased fractional exhaled nitric oxide. Although the Global Initiative for Asthma provides detailed guidelines for SA, patients with marked hypereosinophilia (HE; &gt;1500 cells\/\u00b5L) who do not meet diagnostic criteria for hypereosinophilic syndrome (HES) or eosinophilic granulomatosis with polyangiitis (EGPA) remain insufficiently addressed. In such cases, oral corticosteroids, and T2-targeted monoclonal antibodies (MAbs) inhibiting interleukin-5 or its receptor are the main therapeutic options. For instance, mepolizumab is approved for EGPA, HES, and chronic rhinosinusitis with nasal polyps, but its use in hypereosinophilic SA is limited by eligibility, tolerance, or effectiveness. SA with HE not classified as HES or EGPA is exceptionally rare and may be diagnosed by the exclusion of other potential causes of HE. This review analyzes recent studies and case reports, aiming to expand the understanding of this underrecognized clinical entity, its relation to T2 inflammation and eosinophilic disorders, and to highlight the need for improved diagnostic and therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms26115342","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:40:32Z","timestamp":1748864432000},"page":"5342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Th2-High Severe Asthma with Hypereosinophilia in the Spectrum of Type 2 Inflammatory Diseases"],"prefix":"10.3390","volume":"26","author":[{"given":"Elizabeth","family":"Malaya","sequence":"first","affiliation":[{"name":"Clinic of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Kopci\u0144skiego 22, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Marsza\u0142ek","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Kopci\u0144skiego 22, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Kopci\u0144skiego 22, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kupczyk","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Kopci\u0144skiego 22, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Panek","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Kopci\u0144skiego 22, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Asthma (2025, March 23). Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/2024-report\/."},{"key":"ref_2","unstructured":"World Health Organization: WHO (2025, April 10). Chronic Respiratory Diseases. 15 July 2019. Available online: https:\/\/www.who.int\/health-topics\/chronic-respiratory-diseases#tab=tab_1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103051","DOI":"10.1016\/j.eclinm.2024.103051","article-title":"Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: A systematic analysis of the global burden of disease study 2021","volume":"80","author":"Yuan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_4","unstructured":"Global Initiative for Asthma (2025, March 23). Difficult-to-Treat and Severe Asthma in Adolescent and Adult Patients. Available online: https:\/\/www.ginasthma.org\/severe-asthma."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4168\/aair.2024.16.5.462","article-title":"Update on Inflammatory Biomarkers for Defining Asthma Phenotype","volume":"16","author":"Sim","year":"2024","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103050","DOI":"10.1016\/j.eclinm.2024.103050","article-title":"Roads to remission: Evolving treatment concepts in type 2 inflammatory diseases","volume":"80","author":"Lommatzsch","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1802248","DOI":"10.1183\/13993003.02248-2018","article-title":"Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: A case series","volume":"53","author":"Borie","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"ref_9","unstructured":"Mikhail, E.S., and Ghatol, A. (2025, April 02). Hypereosinophilic Syndrome, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599558\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"AlBloushi, S., and Al-Ahmad, M. (2024). Exploring the immunopathology of type 2 inflammatory airway diseases. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1285598"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hussain, M., and Liu, G. (2024). Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons. Cells, 13.","DOI":"10.3390\/cells13050384"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/DDDT.S300988","article-title":"Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies","volume":"15","author":"Pelaia","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_15","first-page":"100","article-title":"MAPK is implicated in sepsis, immunity, and inflammation","volume":"8","author":"Saggini","year":"2024","journal-title":"Int. J. Infection."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.12775\/JEHS.2023.45.01.028","article-title":"Allergic march: A comprehensive approach to diagnosing, treating and preventing atopic diseases","volume":"45","author":"Suwala","year":"2023","journal-title":"J. Educ. Health Sport"},{"key":"ref_17","unstructured":"Vaillant, A.A.J., Modi, P., Syed, H.A., and Jan, A. (2024). Atopy. Irritant Dermatitis, Springer."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/all.15072","article-title":"IL-37 regulates allergic inflammation by counterbalancing pro-inflammatory IL-1 and IL-33","volume":"77","author":"Lunding","year":"2022","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_19","first-page":"1","article-title":"IL-37 is an inhibitory cytokine that could be useful for treating infections","volume":"8","author":"Toniato","year":"2024","journal-title":"Int. J. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2021","journal-title":"Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","article-title":"The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions","volume":"3","author":"Lombardi","year":"2022","journal-title":"Curr. Res. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/imcb.12819","article-title":"The immunoregulatory potential of eosinophil subsets","volume":"102","author":"Noble","year":"2024","journal-title":"Immunol. Cell Biol."},{"key":"ref_23","unstructured":"Kanuru, S., and Sapra, A. (2023). Eosinophilia. Travel Medicine, Elsevier."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2019.08.005","article-title":"Approach to the patient with eosinophilia","volume":"104","author":"Kuang","year":"2020","journal-title":"Med. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.gpeds.2023.100104","article-title":"Unraveling the diagnostic puzzle of eosinophilia in children","volume":"7","author":"Chiappini","year":"2024","journal-title":"Glob. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Thomsen, G.N., Christoffersen, M.N., Lindegaard, H.M., Davidsen, J.R., Hartmeyer, G.N., Assing, K., Mortz, C.G., Martin-Iguacel, R., M\u00f8ller, M.B., and Kjeldsen, A.D. (2023). The multidisciplinary approach to eosinophilia. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1193730"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.chest.2020.09.247","article-title":"Approach to Eosinophilia Presenting With Pulmonary Symptoms","volume":"159","author":"Rosenberg","year":"2020","journal-title":"Chest"},{"key":"ref_29","first-page":"A1366","article-title":"Chronic Eosinophilic Leukemia Presenting as Asthma","volume":"203","author":"Johnstone","year":"2021","journal-title":"Am. Thorac. Soc. Int. Conf. Meet. Abstr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.alit.2022.10.004","article-title":"Treatments of refractory eosinophilic lung diseases with biologics","volume":"72","author":"Asano","year":"2023","journal-title":"Allergol. Int."},{"key":"ref_31","first-page":"PA4199","article-title":"Late-onset hypereosinophilic asthma accompanied by systemic eosinophilic manifestations","volume":"48","author":"Toyoshima","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ijc.34986","article-title":"Associations between eosinophils and cancer risk in the UK Biobank","volume":"155","author":"Wang","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in Health and Disease: A State-of-the-Art Review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","article-title":"Eosinophils in the tumor microenvironment: Implications for cancer immunotherapy","volume":"21","author":"Ghaffari","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., and Santarpia, M. (2025). The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC. Biomolecules, 15.","DOI":"10.3390\/biom15040491"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"A89","DOI":"10.1016\/j.chest.2023.07.111","article-title":"MARKED HYPEREOSINOPHILIA IN A PATIENT WITH ASTHMA AND NASAL POLYPS CONFOUNDING HYPEREOSINOPHILIC SYNDROME","volume":"164","author":"Gupta","year":"2023","journal-title":"CHEST"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tsurumaki, H., Matsuyama, T., Ezawa, K., Koga, Y., Yatomi, M., Aoki-Saito, H., Chikamatsu, K., and Hisada, T. (2019). Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis. Medicina, 55.","DOI":"10.3390\/medicina55070336"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103336","DOI":"10.1016\/j.annder.2024.103336","article-title":"Efficacy of dupilumab in chronic prurigo: A multicentre retrospective study","volume":"152","author":"Gael","year":"2025","journal-title":"Ann. Dermatol. V\u00e9n\u00e9r\u00e9ologie"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/all.16453","article-title":"Oncostatin-M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma","volume":"80","author":"Esnault","year":"2025","journal-title":"Allergy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaip.2023.02.008","article-title":"Food allergy characteristics associated with co-existing eosinophilic esophagitis in FARE Registry participants","volume":"11","author":"Guarnieri","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Carucci, L., Votto, M., Licari, A., Marseglia, G.L., and Berni Canani, R. (2023). Food allergy: Cause or consequence of pediatric eosinophilic esophagitis? Potential implications of ultraprocessed foods in prevention and management. Front. Allergy, 4.","DOI":"10.3389\/falgy.2023.1138400"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e01431","DOI":"10.1002\/rcr2.1431","article-title":"Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizumab for severe asthma: A case report and literature review","volume":"12","author":"Sakabe","year":"2024","journal-title":"Respirol. Case Rep."},{"key":"ref_43","first-page":"48","article-title":"Hyper eosinophilic diseases\u2014Diagnosis and therapeutic approach\u2014Practical position of the Polish working group","volume":"78","author":"Kuna","year":"2024","journal-title":"Otolaryngol. Pol. Pol. Otolaryngol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaip.2024.10.013","article-title":"Characteristics of Severe Asthma Clinic Patients With Eosinophilic Granulomatosis With Polyangiitis","volume":"13","author":"Puan","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"107414","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody\u2014Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2169\/internalmedicine.7990-21","article-title":"Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab","volume":"61","author":"Ikeda","year":"2022","journal-title":"Intern. Med."},{"key":"ref_48","first-page":"PA5369","article-title":"Asthma loss of control after switch from anti-IL5\/5R drugs to dupilumab in severe eosinophilic asthma: A case series","volume":"64","author":"Poisson","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.14740\/jmc3587","article-title":"COVID-19 Pneumonia or Hypereosinophilic Syndrome?","volume":"11","author":"Serin","year":"2020","journal-title":"J. Med. Cases"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"230126","DOI":"10.1183\/20734735.0126-2023","article-title":"Eosinophilia and wheeze: Thinking beyond asthma","volume":"20","author":"Kuek","year":"2024","journal-title":"Breathe"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.anai.2023.02.022","article-title":"Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization","volume":"130","author":"Hwee","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_52","first-page":"A2031","article-title":"Misdiagnosis of Asthma in a Patient with Hypereosinophilic Syndrome with Cardiac Involvement","volume":"203","author":"Riego","year":"2021","journal-title":"Am. Thorac. Soc. Int. Conf. Meet. Abstr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/07853890.2021.2014555","article-title":"Clinical analysis of hypereosinophilic syndrome first presenting with asthma-like symptoms","volume":"54","author":"Wei","year":"2022","journal-title":"Ann. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"ytad280","DOI":"10.1093\/ehjcr\/ytad280","article-title":"Hypereosinophilic syndrome presenting with progressive cardiac cachexia: A case report","volume":"7","author":"Penz","year":"2023","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102871","DOI":"10.1016\/j.msard.2021.102871","article-title":"Hypereosinophilic syndrome with central nervous system involvement treated with anti-IL-5 therapy","volume":"51","author":"Jonakowski","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.anai.2021.08.270","article-title":"M121 HYPEREOSINOPHILIA IN A PATIENT WITH UNCONTROLLED ASTHMA","volume":"127","author":"Finley","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_57","first-page":"100103","article-title":"Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Alam","year":"2023","journal-title":"Health Sci. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"00048","DOI":"10.1183\/23120541.00048-2024","article-title":"Dupilumab-associated hypereosinophilia in severe asthma","volume":"10","author":"Strong","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_59","first-page":"102136","article-title":"Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma","volume":"52","author":"Przybyszowski","year":"2024","journal-title":"Respir. Med. Case Rep."},{"key":"ref_60","first-page":"857","article-title":"Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma","volume":"85","author":"Masumoto","year":"2023","journal-title":"Nagoya J. Med. Sci."},{"key":"ref_61","first-page":"e49781","article-title":"Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"key":"ref_62","unstructured":"Chowdhury, B.A. (2025, April 10). Center for Drug Evaluation and Research Application Number: 125526Orig1s000 Summary Review Summary Review of Regulatory Action. Available online: https:\/\/www.ginasthma.org\/."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1007\/s12325-024-02967-x","article-title":"Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)","volume":"41","author":"Maturu","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2024\u20133-5","DOI":"10.7573\/dic.2024-3-5","article-title":"Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: The importance of multidisciplinary management. A case report and literature review","volume":"13","author":"Munari","year":"2024","journal-title":"Drugs Context"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2147\/JAA.S499026","article-title":"Possible Biological Heterogeneity of Airway Mucus Plugs in a Patient with Asthma","volume":"17","author":"Tashiro","year":"2024","journal-title":"J. Asthma Allergy"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109131","DOI":"10.1016\/j.intimp.2022.109131","article-title":"Efficacy and safety of treatment with benralizumab for eosinophilic asthma","volume":"111","author":"Zhu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"107611","DOI":"10.1016\/j.rmed.2024.107611","article-title":"Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia","volume":"229","author":"Lai","year":"2024","journal-title":"Respir. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pini, L., Bagnasco, D., Begh\u00e8, B., Braido, F., Cameli, P., Caminati, M., Caruso, C., Crimi, C., Guarnieri, G., and Latorre, M. (2024). Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. J. Clin. Med., 13.","DOI":"10.20944\/preprints202402.1390.v1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.pupt.2020.101965","article-title":"Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps","volume":"64","author":"Matsuno","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"00339","DOI":"10.1183\/23120541.00339-2020","article-title":"Childhood-onset severe hypereosinophilic asthma: Efficacy of benralizumab","volume":"6","author":"Just","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/JAA.S340562","article-title":"Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data","volume":"15","author":"Campos","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","article-title":"Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma\u2014First Initiators and Switchers","volume":"10","author":"Hashimoto","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1159\/000519471","article-title":"Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report","volume":"14","author":"Park","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4168\/aair.2020.12.2.371","article-title":"Non-episodic Angioedema With Eosinophilia Successfully Treated With Reslizumab","volume":"12","author":"Chu","year":"2020","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2023.02.013","article-title":"HES and EGPA: Two Sides of the Same Coin","volume":"98","author":"Khoury","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/JAA.S418145","article-title":"Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma","volume":"16","author":"Rabe","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4168\/aard.2019.7.3.142","article-title":"Etiologies and differential markers of eosinophilia-associated diseases in the Allergy Department of a single university hospital","volume":"7","author":"Yu","year":"2019","journal-title":"Allergy Asthma Respir. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2147\/JAA.S472490","article-title":"Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction","volume":"17","year":"2024","journal-title":"J. Asthma Allergy"},{"key":"ref_81","first-page":"215","article-title":"Korean Adolescent Patient with Manifestations of Lymphocyte Variant Hypereosinophilic Syndrome and Episodic Angioedema with Eosinophilia, Treated with Reslizumab","volume":"21","author":"Jue","year":"2022","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Sun, Y., and Chen, S.N. (2023). Case Report: Off-label treatment of idiopathic hypereosinophilic syndrome with Omalizumab. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1095737"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.radcr.2024.11.091","article-title":"Myocarditis with neurological and dermatological involvement in idiopathic Hypereosinophilic syndrome: Case report","volume":"20","author":"Ihssane","year":"2025","journal-title":"Radiol. Case Rep."},{"key":"ref_84","unstructured":"Panek, M., Majos, A., and Kupczyk, M. (2025, January 9\u201312). Rekwalifikacja pacjenta w trakcie terapii biologicznej astmy ci\u0119\u017ckiej [Conference presentation]. Proceedings of the 17. Konferencja Szkoleniowa Polskiego Towarzystwa Alergologicznego (PTA), Toru\u0144, Poland."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.abd.2023.12.010","article-title":"DRESS syndrome: An interaction between drugs, latent viruses, and the immune system","volume":"100","author":"Criado","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chen, C.B., Hung, W.K., Wang, C.W., Lee, C.C., Hung, S.I., and Chung, W.H. (2023). Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: An updated review. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1187937"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5342\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:03Z","timestamp":1760031963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115342"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115342","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}